From Code
to Cure®
pioneer in computational drug target discovery
Innovative immuno-oncology pipeline

NEWS

ALL NEWS

Research and Development

Our optimized process for predictive discovery of novel drug targets
READ MORE

Clinical Development

Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
READ MORE

Compugen, FROM CODE TO CURE

Our Pipeline

COM701/PVRIG

COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally by Compugen.
READ MORE

BAY 1905254/ILDR2 (partnered)

ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer.
READ MORE

COM902/TIGIT

COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701.

COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701
READ MORE

Multiple myeloid programs

Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action.
READ MORE
MORE EVENTS

Collaborations

Click here for more info about partnering with Compugen